Dr. Barry DiBernardo’s Testimony on Fat Removal Laser Leads to Deense Verdict in Product Liability Case

Javascript is required to watch this video

If you have enabled JavaScript and still cannot play the video, please contact support.

During a 2019 product liability trial, Dr. Barry DiBernardo, a New Jersey plastic surgeon, testifies for the defense against a claim by the plaintiff that a defect in a laser fat removal system left the patient with permanent pain and scarring. The expert in this case was a lead investigator for this new laser treatment.

DiBernardo begins by explaining that the plaintiff had a previous liposuction procedure in the area to be reoperated on and that performing the procedure under these circumstances was contraindicated according to the instrument’s manual. It was also especially unwise given that this was the surgeon’s first time using the new “Cellulaze” system. As such, the expert felt that this would breach the standard of care for plastic surgeons under the circumstances. 

The patient, the expert maintains, was not a good candidate for this newly developed fat removal system and her post-operative poor outcome was related to the physician’s inexperience and his use of the Cellulaze in an area that had been previously damaged by liposuction. His contention was that the instrument was not defective, the patient selection was.

Dibernardo goes on to explain why he believes the Cellulaze’s use was contraindicated in this patient. He explains that the fact that the patient had been previously treated with liposuction could easily complicate the attempts to contour cellulite with the new laser system by causing irregularities due to scarring and disruption of blood supply.  For instance, the previous surgery would have disrupted veins and lymphatic vessels leading to excessive swelling post operatively. 

Even more importantly, the Cellulaze system is not designed to deal with postoperative scarring that would be encountered in a patient that has had liposuction. The small laser system can disrupt the structure of normal fat cells, not those that have been previously damaged, and the patient’s normal connective tissue between the fat collections can be purposely disrupted by the Cellulaze system to smooth the small depressions of true cellulite. Using this laser to disrupt either previously damaged fat cells or scar tissue bands will lead to inconsistent results, at best. 

The expert also notes that this system is designed only to deal with the immediately subdermal fat that causes cellulite, not the deep fat that causes major contour problems. The previous liposuction will cause irregularities in the contour of the skin from scarring that may give it the appearance of cellulite, when it is not. Cellulaze has been developed just for the treatment of cellulite. If the depressions and bulges in the skin are not due to true cellulite, then the treatment with the Cellulaze product is far less likely to produce a favorable outcome. In other words, the sort of post -liposuction problems that produce large depressions and fat bulges will be inadequately treated with this small laser system and will require repeat liposuction and fat grafting.

DiBernardo stresses it was unreasonable for the surgeon to have attempted to treat such a complicated case with his first use of the Cellulaze. He was just learning how the system works, yet he chose to operate on a patient with contraindications. This more likely led to the unsatisfactory outcome rather than any defect in the Cellulaze laser system. 

The jury agreed, rendering a verdict for the defense.

--

Gary Gansar, MD, is residency trained and Board Certified in General Surgery. He previously served as Chief of Surgery and Staff at Elmwood Medical Center and on the Medical Executive Committee at Mercy Hospital and Touro Infirmary in New Orleans, LA. Dr. Gansar also served as Clinical Instructor and Professor of Surgery at Tulane University. He received his MD and served as Chief Resident at Tulane University Medical School. Dr. Gansar joined AMFS as a consulting medical expert in 2011 and has served as Medical Director since Nov. 2015. In this capacity, Dr. Gansar provides consultation, review and guidance to attorney clients.

View Similar Clips

More from the Proceeding
Adriana Diaz, et al. v. Cynosure Inc., et al.
More from Industry
Health care
More from Practice Area
Products Liability

Suggest a Trial

Want to see a trial that you don't see in our list of upcoming trials?

Suggest a Case

CVN Essentials

The most important and informative moments of each trial

CVN Essentials

Video Library

Unlimited access to thousands of hours of past coverage of high stakes civil litigation

Video Library

  • Follow Us
  • Contact Us
  • 4901 Olde Towne Parkway
  • Suite 100
  • Marietta, GA 30068
  • 877-834-8627
  • 404-935-0321

Copyright 2024 Courtroom Connect.